Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Long-Term Debt Repayments (2019 - 2024)

Historic Long-Term Debt Repayments for Sutro Biopharma (STRO) over the last 5 years, with Q1 2024 value amounting to $4.1 million.

  • Sutro Biopharma's Long-Term Debt Repayments rose 3065.6% to $4.1 million in Q1 2024 from the same period last year, while for Dec 2024 it was $4.1 million, marking a year-over-year decrease of 6733.6%. This contributed to the annual value of $4.1 million for FY2024, which is 6733.6% down from last year.
  • As of Q1 2024, Sutro Biopharma's Long-Term Debt Repayments stood at $4.1 million, which was up 3065.6% from $3.1 million recorded in Q4 2023.
  • In the past 5 years, Sutro Biopharma's Long-Term Debt Repayments ranged from a high of $10.0 million in Q1 2020 and a low of $3.1 million during Q3 2022
  • For the 4-year period, Sutro Biopharma's Long-Term Debt Repayments averaged around $4.1 million, with its median value being $3.1 million (2022).
  • Its Long-Term Debt Repayments has fluctuated over the past 5 years, first surged by 190000.0% in 2020, then changed by 0.0% in 2023.
  • Sutro Biopharma's Long-Term Debt Repayments (Quarter) stood at $10.0 million in 2020, then plummeted by 68.75% to $3.1 million in 2022, then changed by 0.0% to $3.1 million in 2023, then surged by 30.66% to $4.1 million in 2024.
  • Its Long-Term Debt Repayments stands at $4.1 million for Q1 2024, versus $3.1 million for Q4 2023 and $3.1 million for Q3 2023.